Skip to content
TrialScanner

NCT03623321

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Phase 3CompletedACADLead

Registry record

Lead sponsor
ACADIA Pharmaceuticals Inc.
Conditions
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Primary completion
May 5, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03623321 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03623321: Extension Study of Pimavanser... | TrialScanner